

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58881 A1(51) International Patent Classification: C07D 239/42,
401/12, 407/12, 409/12, 417/12, A61K 31/505, 31/506,
A61P 29/00ple, Gunned Wood Road, Stevenage, Hertfordshire SG1
2NY (GB).

(21) International Application Number: PCT/GB01/00511

(74) Agent: LANE, Graham; GlaxoSmithKline, Corporate In-
tellectual Property, Two New Horizons Court, Brentford,
Middlesex, TW8 9EP (GB).

(22) International Filing Date: 8 February 2001 (08.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0003224.3 11 February 2000 (11.02.2000) GB

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(71) Applicant (for all designated States except US): GLAXO
GROUP LIMITED [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): CARTER, Mal-
colm, Clive [GB/GB]; Glaxo Wellcome plc, Gunned
Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).
NAYLOR, Alan [GB/GB]; Glaxo Wellcome plc, Gunned
Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).
PAYNE, Jeremy, John [GB/GB]; Glaxo Wellcome plc,
Gunned Wood Road, Stevenage, Hertfordshire SG1 2NY
(GB). PEGG, Neil, Anthony [GB/GB]; Glaxo Wellcome

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2

(57) Abstract: The invention provides the
compounds of formula (I) and pharmaceutically
acceptable derivatives thereof, in which: R¹ and
R² are independently selected from H, or C₁₋₆alkyl,
R³ is C₁₋₆alkyl or NH₂; R⁴ is H or C₁₋₆alkyl; A is
a 5- or 6-membered aryl, or a 5- or 6-membered
aryl substituted by one or more R³; R² is halogen,
C₁₋₆alkyl, C₁₋₆alkyl substituted by one or more F,
C₁₋₆alkoxy, C₁₋₆alkoxy substituted by one or more F,
SO₂NH₂ or SO₂C₁₋₆alkyl; and n is 1 to 4. Compounds
of formula (I) are potent and selective inhibitors of
COX-2 and are of use in the treatment of the pain,


fever, inflammation of a variety of conditions and diseases.

WO 01/58881 A1

PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2

This invention relates to pyrimidine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.

- 5 The enzyme cyclooxygenase (COX) has recently been discovered to exist in two isoforms, COX-1 and COX-2. COX-1 corresponds to the originally identified constitutive enzyme while COX-2 is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. Prostaglandins generated by the action of COX have both physiological and
- 10 pathological roles. It is generally believed that COX-1 is largely responsible for the important physiological functions such as maintenance of gastrointestinal integrity and renal blood flow. In contrast the inducible form, COX-2, is believed to be largely responsible for the pathological effects of prostaglandins where rapid induction of the enzyme occurs in response to such agents as
- 15 inflammatory agents, hormones, growth factors and cytokines. A selective inhibitor of COX-2 would therefore have anti-inflammatory, anti-pyretic and analgesic properties, without the potential side effects associated with inhibition of COX-1. We have now found a novel group of compounds which are both potent and selective inhibitors of COX-2.
- 20 The invention thus provides the compounds of formula (I)



and pharmaceutically acceptable derivatives thereof, in which:

- R^1 and R^2 are independently selected from H, or C_{1-6} alkyl;
- R^3 is C_{1-6} alkyl or NH_2 ;
- 25 R^4 is H or C_{1-6} alkyl;
- A is a 5- or 6-membered aryl, or a 5- or 6-membered aryl substituted by one or more R^5 ;

R⁵ is halogen, C₁₋₆alkyl, C₁₋₆alkyl substituted by one or more F, C₁₋₆alkoxy, C₁₋₆alkoxy substituted by one or more F, SO₂NH₂ or SO₂C₁₋₆alkyl; and n is 1 to 4.

5 By pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide, of the compounds of formula (I), or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.

10 It will be appreciated by those skilled in the art that the compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds. Of particular interest as such derivatives are compounds modified at the benzenesulphonamide function to provide metabolically labile benzenesulphonamides. Acylated benzenesulphonamide derivatives are of especial interest.

15 It will be appreciated by those skilled in the art that the pharmaceutically acceptable derivatives of the compounds of formula (I) may be derivatised at more than one position.

It will be further appreciated by those skilled in the art that benzenesulphonamide derivatives of formula (I) may be useful as intermediates
20 in the preparation of compounds of formula (I), or as pharmaceutically acceptable derivatives of formula (I), or both.

It will be appreciated that, for pharmaceutical use, the salts referred to above will be the physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the physiologically acceptable
25 salts thereof.


Suitable pharmaceutically acceptable salts include: acid addition salts formed with inorganic or organic acids, preferably inorganic acids, e.g. hydrochlorides, hydrobromides and sulphates; and alkali metal salts, formed from addition of alkali metal bases, such as alkali metal hydroxides, e.g. sodium salts.

30 The term halogen is used to represent fluorine, chlorine, bromine or iodine.


The term 'alkyl' as a group or part of a group means a straight or branched chain alkyl group, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl or t-butyl group.

The term 5-membered aryl means an aryl selected from the following:

5



The term 6-membered aryl means aryl selected from:



10 It will be appreciated by those skilled in the art that when R^1 and R^2 in formula (I) are different the corresponding compounds contain at least one chiral centre, by virtue of the asymmetric carbon atom defined thereby, and that such compounds exist in the form of a pair of optical isomers (i.e. enantiomers).


15 It is to be understood that the present invention encompasses all isomers of the compounds of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures).

In one aspect of the invention R^1 and R^2 are independently selected from H or methyl. In another aspect R^1 and R^2 are both H.

20 In another aspect of the invention R^3 is C_{1-6} alkyl, such as C_{1-3} alkyl (e.g. methyl).

In another aspect of the invention, R^4 is H or C_{1-3} alkyl, such as methyl.

In another aspect of the invention A is selected from



and A is unsubstituted or substituted by one or two R^5 (e.g. one R^5).

In another aspect of the invention A is selected from



- 5 In another aspect of the invention R^5 is halogen (e.g. F), C_{1-3} alkyl (e.g. methyl), C_{1-3} alkyl substituted by one to three F (e.g. CF_3), C_{1-3} alkoxy (e.g. methoxy), C_{1-3} alkoxy substituted by one to three F (e.g. $OCHF_2$ or OCF_3), or $SONH_2$.


In another aspect of the invention R^5 is halogen (e.g. F) or C_{1-6} alkoxy, such as C_{1-3} alkoxy (e.g. methoxy).

- 10 In another aspect of the invention n is 1 to 3 (e.g. 1).

It is to be understood that the invention covers all combinations of particular aspects of the invention as described hereinabove.


- 15 Within the invention there is provided one group of compounds of formula (I) (group A) wherein: R^1 and R^2 are independently selected from H or methyl; R^3 is C_{1-6} alkyl, such as C_{1-3} alkyl (e.g. methyl); R^4 is H or C_{1-3} alkyl, such as methyl; A is selected from

5




and is unsubstituted or substituted by one or two R^5 (e.g. one R^5); R^5 is halogen (e.g. F), C_{1-3} alkyl (e.g. methyl), C_{1-3} alkyl substituted by one to three F (e.g. CF_3), C_{1-3} alkoxy (e.g. methoxy), C_{1-3} alkoxy substituted by one to three F (e.g. $OCHF_2$ or OCF_3), or $SONH_2$; and n is 1 to 3 (e.g. 1).

- 5 Within the invention there is provided another group of compounds of formula (I) (group B) wherein: R^1 and R^2 are independently selected from H or methyl; R^3 is C_{1-6} alkyl, such as C_{1-3} alkyl (e.g. methyl); R^4 is H or C_{1-3} alkyl, such as methyl; A is selected from



- 10 R^5 is halogen (e.g. F), C_{1-3} alkyl (e.g. methyl), C_{1-3} alkyl substituted by one to three F (e.g. CF_3), C_{1-3} alkoxy (e.g. methoxy), C_{1-3} alkoxy substituted by one to three F (e.g. $OCHF_2$ or OCF_3), or $SONH_2$; and n is 1 to 3 (e.g. 1).

- 15 Within the invention there is provided another group of compounds of formula (I) (group C) wherein: R^1 and R^2 are independently selected from H or methyl; R^3 is C_{1-6} alkyl, such as C_{1-3} alkyl (e.g. methyl); R^4 is H or C_{1-3} alkyl, such as methyl; A is selected from



R⁵ is halogen (e.g. F) or C₁₋₆alkoxy, such as C₁₋₃alkoxy (e.g. methoxy); and n is 1 to 3 (e.g. 1).

In another aspect of the invention, R¹ and R² in the compounds of groups A, B and C are both H.

- 5 In another aspect the invention provides the following compounds:
4-[4-(methylsulfonyl)phenyl]-N-(pyridin-4-ylmethyl)-6-(trifluoromethyl)pyrimidin-2-amine;
4-[4-(methylsulfonyl)phenyl]-N-(pyridin-3-ylmethyl)-6-(trifluoromethyl)pyrimidin-2-amine;
10 4-[4-(methylsulfonyl)phenyl]-N-(pyridin-2-ylmethyl)-6-(trifluoromethyl)pyrimidin-2-amine;
4-[4-(methylsulfonyl)phenyl]-N-(phenylmethyl)-6-(trifluoromethyl)-2-pyrimidinamine;
N-(4-methoxybenzyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine;
15 N-(4-fluorobenzyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine;
and pharmaceutically acceptable derivatives thereof.

- 20 Compounds of the invention are potent and selective inhibitors of COX-2. This activity is illustrated by their ability to selectively inhibit COX-2 over COX-1.

- In view of their selective COX-2 inhibitory activity, the compounds of the present invention are of interest for use in human and veterinary medicine, particularly in the treatment of the pain (both chronic and acute), fever and inflammation of a variety of conditions and diseases mediated by COX-2. Such conditions and diseases are well known in the art and include rheumatic fever; symptoms associated with influenza or other viral infections, such as the common cold; lower back and neck pain; headache; toothache; sprains and strains; myositis; sympathetically maintained pain; synovitis; arthritis, including rheumatoid arthritis; degenerative joint diseases, including osteoarthritis; gout and
25 ankylosing spondylitis; tendinitis; bursitis; skin related conditions, such as psoriasis, eczema, burns and dermatitis; injuries, such as sports injuries and those arising from surgical and dental procedures.
30

The compounds of the invention are also useful for the treatment of neuropathic pain. Neuropathic pain syndromes can develop following neuronal injury and the resulting pain may persist for months or years, even after the original injury has healed. Neuronal injury may occur in the peripheral nerves, dorsal roots, spinal cord or certain regions in the brain. Neuropathic pain syndromes are traditionally classified according to the disease or event that precipitated them. Neuropathic pain syndromes include: diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; neuralgia, such as post-herpetic neuralgia and trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions. These conditions are difficult to treat and although several drugs are known to have limited efficacy, complete pain control is rarely achieved. The symptoms of neuropathic pain are incredibly heterogeneous and are often described as spontaneous shooting and lancinating pain, or ongoing, burning pain. In addition, there is pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).

The compounds of the invention are also useful for the treatment of other conditions mediated by COX-2.

For example, the compounds of the invention inhibit cellular and neoplastic transformation and metastatic tumour growth and hence are useful in the treatment of certain cancerous diseases, such as colonic cancer and prostate cancer. The compounds of the invention are also useful in reducing the number of adenomatous colorectal polyps and thus reduce the risk of developing colon cancer. The compounds of the invention are also useful in the treatment of cancer associated with overexpression of HER-2/neu, in particular breast cancer.

Compounds of the invention also prevent neuronal injury by inhibiting the generation of neuronal free radicals (and hence oxidative stress) and therefore

are of use in the treatment of stroke; epilepsy; and epileptic seizures (including grand mal, petit mal, myoclonic epilepsy and partial seizures).

Compounds of the invention also inhibit prostanoid-induced smooth muscle contraction and hence are of use in the treatment of dysmenorrhoea and premature labour.

Compounds of the invention are also useful in the treatment of liver disease, such as inflammatory liver disease, for example chronic viral hepatitis B, chronic viral hepatitis C, alcoholic liver injury, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis and liver transplant rejection.

Compounds of the invention inhibit inflammatory processes and therefore are of use in the treatment of asthma, allergic rhinitis and respiratory distress syndrome; gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis; and the inflammation in such diseases as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin's disease, sclerodoma, type I diabetes, myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, conjunctivitis and myocardial ischemia.

Compounds of the invention are also useful in the treatment of ophthalmic diseases such as retinitis, retinopathies, uveitis and of acute injury to the eye tissue.

Compounds of the invention are also useful for the treatment of cognitive disorders such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntington's chorea, Parkinson's disease and Creutzfeldt-Jakob disease), and vascular dementia (including multi-infarct dementia), as well as dementia associated with intracranial space occupying lesions, trauma, infections and related conditions (including HIV infection), metabolism, toxins, anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment.

According to a further aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine.

- 5 According to another aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by COX-2.

- 10 According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from a condition which is mediated by COX-2 which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative.

According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from an inflammatory disorder, which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

- 15 According to another aspect of the invention, we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment of a condition which is mediated by COX-2.

- 20 According to another aspect of the invention, we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment of an inflammatory disorder.

- 25 It is to be understood that reference to treatment includes both treatment of established symptoms and prophylactic treatment, unless explicitly stated otherwise.

- 30 It will be appreciated that the compounds of the invention may advantageously be used in conjunction with one or more other therapeutic agents. Examples of suitable agents for adjunctive therapy include a 5HT₁ agonist, such as a triptan (e.g. sumatriptan or naratriptan); an adenosine A₁ agonist; an EP ligand (e.g. an EP₄ antagonist); an NMDA modulator, such as a glycine antagonist; a sodium channel blocker (e.g. lamotrigine); a substance P antagonist (e.g. an NK₁

antagonist); a cannabinoid; acetaminophen or phenacetin; a 5-lipoxygenase inhibitor; a leukotriene receptor antagonist; a DMARD (e.g. methotrexate); gabapentin and related compounds; a tricyclic antidepressant (e.g. amitriptyline); a neurone stabilising antiepileptic drug; a mono-aminergic uptake inhibitor (e.g. venlafaxine); a matrix metalloproteinase inhibitor; a nitric oxide synthase (NOS) inhibitor, such as an iNOS or an nNOS inhibitor; an inhibitor of the release, or action, of tumour necrosis factor α ; an antibody therapy, such as a monoclonal antibody therapy; an antiviral agent, such as a nucleoside inhibitor (e.g. lamivudine) or an immune system modulator (e.g. interferon); an opioid analgesic; a local anaesthetic; a stimulant, including caffeine; an H_2 -antagonist (e.g. ranitidine); a proton pump inhibitor (e.g. omeprazole); an antacid (e.g. aluminium or magnesium hydroxide); an antifatulent (e.g. simethicone); a decongestant (e.g. phenylephrine, phenylpropanolamine, pseudoephedrine, oxymetazoline, epinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine); an antitussive (e.g. codeine, hydrocodone, carmiphen, carbetapentane, or dextramethorphan); a diuretic; or a sedating or non-sedating antihistamine. It is to be understood that the present invention covers the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in combination with one or more other therapeutic agents.

The compounds of formula (I) and their pharmaceutically acceptable derivatives are conveniently administered in the form of pharmaceutical compositions. Thus, in another aspect of the invention, we provide a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof adapted for use in human or veterinary medicine. Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients.

The compounds of formula (I) and their pharmaceutically acceptable derivatives may be formulated for administration in any suitable manner. They may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration. The pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable derivatives.

For oral administration, the pharmaceutical composition may take the form of, for example, tablets (including sub-lingual tablets), capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.

- 5 For transdermal administration, the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.

- For parenteral administration, the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously). The compositions may take such forms as suspensions,
10 solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative.

- Alternatively for parenteral administration the active ingredient may be in powder
15 form for reconstitution with a suitable vehicle.

- The compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable
20 polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

- As stated above, the compounds of the invention may also be used in combination with other therapeutic agents. The invention thus provides, in a
25 further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent.

- The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations
30 comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either

sequentially or simultaneously in separate or combined pharmaceutical formulations.

When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

A proposed daily dosage of a compound of formula (I) for the treatment of man is 0.01mg/kg to 500mg/kg, such as 0.05mg/kg to 100mg/kg, e.g. 0.1mg/kg to 50mg/kg, which may be conveniently administered in 1 to 4 doses. The precise dose employed will depend on the age and condition of the patient and on the route of administration. Thus, for example, a daily dose of 0.25mg/kg to 10mg/kg may be suitable for systemic administration.


Compounds of formula (I) and pharmaceutically acceptable derivatives thereof may be prepared by any method known in the art for the preparation of compounds of analogous structure.

Suitable methods for the preparation of compounds of formula (I) and pharmaceutically acceptable derivatives thereof follow. In Scheme 1 and its variations, R^1 to R^4 , n and A are as defined in formula (I) above unless otherwise stated; Hal is a halogen, such as Cl or Br; MTBE is methyl t-butyl ether; and alkyl is a straight or branched chain alkyl group, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl or t-butyl group.

Referring to Scheme 1, the treatment of compounds of formula (III) with an amine of formula (II) is conveniently carried out in a solvent, such as a nitrile (e.g. methylnitrile) and at elevated temperature (e.g. from about 50°C to reflux). An excess of the amine may be used in place of the solvent.

Conveniently, the boronic acid coupling shown in Scheme 1 is carried out in a solvent, such as an ether (e.g. 1,2-dimethoxyethane); in the presence of a base, such as an inorganic base (e.g. sodium carbonate); and employing a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0).

Scheme 1




Conveniently the oxidation shown in Scheme 1 is effected using a monopersulfate compound, such as potassium peroxymonosulfate (known as OxoneTM) and the reaction is carried out in a solvent, such as an aqueous alcohol, (e.g. aqueous methanol), and at between -78°C and ambient temperature.

Referring to Scheme 1, the cyclisation of diones of formula (VI) to give the corresponding pyrimidines of formula (IV) is conveniently carried out employing a thioronium salt such as a 2-methyl-2-thiopseudourea sulfate and under reflux.

It will be appreciated by those skilled in the art that certain of the procedures described in Scheme 1 for the preparation of compounds of formula (I) or intermediates thereto may not be applicable to some of the possible substituents.

It will be further appreciated by those skilled in the art that it may be necessary or desirable to carry out the transformations described in Scheme 1 in a different order from that described, or to modify one or more of the transformations, to provide the desired compound of formula (I).


In one variation of Scheme 1 (scheme 1A), compounds of formula (III) wherein R³ is C₁₋₆alkyl may be prepared by oxidising a disulphide of formula (IV)A:



under oxidation conditions described hereinabove. Disulphides of formula (IV)A may be prepared according to the general procedures of Scheme 1 by employing sulphide derivatives in place of the corresponding alkylsulphonyl compounds of formulae (VII) and (VIII).

In another variation of scheme 1 (scheme 1B), compounds of formula (I) wherein R⁴ is H may be prepared from the corresponding formamyl derivative, as illustrated below.

Scheme 1B



- 5 It will be appreciated by those skilled in the art that compounds of formula (I) may be prepared by interconversion, utilising other compounds of formula (I) as precursors. Suitable interconversions, such as alkylations, are well known to those skilled in the art and are described in many standard organic chemistry texts, such as 'Advanced Organic Chemistry' by Jerry March, fourth edition
- 10 (Wiley, 1992), incorporated herein by reference. For example, compounds of

formula (I) wherein R^4 is C_{1-6} alkyl may be prepared by alkylating the corresponding compound of formula (I) wherein R^4 is H.

- 5 Acylation of compounds of formula (I) wherein R^3 is NH_2 to provide corresponding acylated benzenesulphonamide derivatives may be carried out by conventional means, for example by employing conventional acylating agents such as those described in 'Advanced Organic Chemistry', pp 417-424.

- 10 As will be appreciated by those skilled in the art it may be necessary or desirable at any stage in the synthesis of compounds of formula (I) to protect one or more sensitive groups in the molecule so as to prevent undesirable side reactions. The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See, for example, those described in 'Protective Groups in Organic Synthesis' by Theodora W Green and Peter G M Wuts, second edition, (John Wiley and Sons, 1991), incorporated herein by reference, which also describes methods for the removal of such groups.

- 15 Amines of formula (II) are either known compounds or may be prepared by literature methods, such as those described in 'Comprehensive Organic Transformations: a guide to functional group preparations' by Richard Larock (VCH, 1989), incorporated herein by reference.

- 20 Thionium salts of formula (V) are either known compounds or may be prepared by literature methods, such as those described in A H Owens *et al*, Eur J Med Chem, 1988, 23(3), 295-300, incorporated herein by reference

Acetophenones of formula (VII) are either known compounds or may be prepared by conventional chemistry.

- 25 Boronic acids of formula (VIII) or derivatives thereof are either known compounds or may be prepared by literature methods, such as those described in EPA publication No. 533268; or R Miyaura *et al*, J Org Chem, 1995, 60, 7508-7510; each incorporated herein by reference.

- 30 4-Halo-6-trifluoromethylpyrimidines of formula (IX) are either known compounds or may be prepared by literature methods, such as those described in Japanese Patent no. 42014952 (Chem Abs ref CAN 68:105224), incorporated herein by reference.

Alkyl halides of formula (XII) are either known compounds or may be prepared by conventional chemistry.

- 5 Certain intermediates described above are novel compounds, and it is to be understood that all novel intermediates herein form further aspects of the present invention. Compounds of formulae (III), (IV) and (XIII) are key intermediates and represent a particular aspect of the present invention.

Conveniently, compounds of the invention are isolated following work-up in the form of the free base. Pharmaceutically acceptable acid addition salts of the compounds of the invention may be prepared using conventional means.

- 10 Solvates (e.g. hydrates) of a compound of the invention may be formed during the work-up procedure of one of the aforementioned process steps.

- The Intermediates and Examples that follow illustrate the invention but do not limit the invention in any way. All temperatures are in °C. Flash column chromatography was carried out using Merck 9385 silica. Solid Phase
15 Extraction (SPE) chromatography was carried out using Varian Mega Bond Elut (Si) cartridges (Anachem) under 15mmHg vacuum with stepped gradient elution. Thin layer chromatography (Tlc) was carried out on silica plates. In addition to those already defined, the following abbreviations are used:
Me, methyl; Ac, acyl; DMSO, dimethylsulphoxide; TFA, trifluoroacetic acid;
20 DME, dimethoxyethane; THF, tetrahydrofuran; DCM, dichloromethane; and MTBE, methyl t-butyl ether.

Intermediate 14,4,4-Trifluoro-1-[4-(methylthio)phenyl]butane-1,3-dione

To a solution of ethyl trifluoroacetate (7.95ml, 1.1eq) in MTBE (125ml) was added dropwise 25% sodium methoxide in methanol (16ml, 1.2eq).
5 4-Methylthioacetophenone (Aldrich, 10g, 0.06mol) was added portionwise and the mixture stirred at ambient temperature overnight. 2N Hydrochloric acid (40ml) was added cautiously and the organic phase separated, washed with brine and dried (Na₂SO₄) to give an orange solid. The orange solid was recrystallised from hot isopropanol to give the title compound as a yellow
10 crystalline solid (11.25g, 71%).

MH- 261

Intermediate 22-(Methylthio)-4-[4-(methylthio)phenyl]-6-(trifluoromethyl) pyrimidine

15 To a mixture of 4,4,4-trifluoro-1-[4-(methylthio)phenyl]butane-1,3-dione (5g) and 2-methyl-2-thiopseudourea sulfate (5.1g, 0.98eq) in acetic acid (100ml) was added sodium acetate (3g, 2eq) and heated under reflux for 8h. The mixture was concentrated *in vacuo* and water (100ml) added to give a solid, which was isolated by filtration to give the title compound as a yellow solid (5.8g,
20 quantitative).

MH+ 317

Intermediate 32-(Methylthio)-4-[4-(methylthio)phenyl]-6-(trifluoromethyl) pyrimidine

25 A mixture of 4-chloro-2-methylthio-6-(trifluoromethyl)pyrimidine (ButtPark Ltd, 2.86g, 14.55mmol), 4-(methylthio)phenylboronic acid (Aldrich, 2.83g, 1.1eq), tetrakis(triphenylphosphine) palladium (0) (0.2g) and sodium carbonate (4.04g, 2.6eq) in DME (200ml) and water (100ml) was heated under reflux with stirring under N₂ for 24h. The reaction mixture was concentrated *in vacuo* and the
30 resultant mixture partitioned between ethyl acetate and water. The organic phase was separated, washed with water, dried (Na₂SO₄) and concentrated *in vacuo* to a purple solid. Purification by flash column chromatography with cyclohexane:ethyl acetate as (6:1) as eluant gave the title compound as a yellow
crystalline solid (3.86g, 84%).

MH+ 317

Tlc SiO₂ cyclohexane:ethyl acetate (3:1) R_f 0.75 *uv*₂₅₄

Intermediate 42-(Methylsulfonyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine

- 5 To a solution of 2-(methylthio)-4-[4-(methylthio)phenyl]-6-(trifluoromethyl)pyrimidine (5.78g) in MeOH (500ml) was added a solution of OXONE™ (Aldrich, 56.23g, 5eq) in water (200ml). The mixture was stirred at ambient temperature overnight, concentrated *in vacuo* and the residue partitioned between water and ethyl acetate (2 x 100ml). The combined organic phases were dried and concentrated *in vacuo* to an off-white solid which was triturated with hot
10 isopropanol to give the title compound as a white solid (5.6g, 80%).

MH+ 381

Tlc SiO₂ Ethyl acetate:cyclohexane (1:1) Rf 0.45Intermediate 5

- 15 4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine

- A solution of 2-(methylsulfonyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (2g, 5.258mmol) in acetonitrile (30ml) was treated with 0.880 ammonia (6ml) dropwise. The resulting mixture was then stirred at 20C for 18h. This gave the title compound as a colourless precipitate which was
20 collected by filtration and dried (1.53g)

MH- = 316

Intermediate 6

- 25 4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-ylformamide

- A mixture of formic acid (7ml) and acetic anhydride (2ml) was stirred at 20C for 1h. 4-[4-(Methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine (0.5g, 1.576mmol) was then added and stirring was continued at ambient temperature for 18h. This gave the title compound as a colourless precipitate which was
30 collected by filtration and dried (0.32g).

MH+ = 346

Intermediate 7

- (5-methyl-1H-imidazol-4-yl)methyl[4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2yl]formamide

- 35 To a stirred solution of 4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-ylformamide (0.5g, 1.54mmol) in dry dimethylformamide (10ml) under N₂ was

added sodium hydride (60% dispersion in oil, 0.16g). The mixture was stirred for 30 mins, 4-(chloromethyl)-5-methyl-1H-imidazole, hydrochloride (0.283g) was added and stirring was then continued at room temp for 18h. The mixture was then partitioned between water and ethyl acetate. The extracts were dried (Na₂SO₄) and evaporated. The residue was then triturated with diethyl ether giving the crude title compound as a pale yellow solid (0.27g).
MH+= 440

Example 1

4-[4-(Methylsulfonyl)phenyl]-N-(pyridin-4-ylmethyl)-6-(trifluoromethyl)pyrimidin-2-amine

To a stirred solution of 2-(methylsulfonyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (0.10g, 0.26mmol) in MeCN (4ml) was added 4-(aminomethyl)-pyridine (0.14ml, 5eq) and the resultant solution heated under reflux for 18h. The cooled reaction mixture was concentrated *in vacuo* and purified by SPE chromatography using chloroform, diethyl ether, ethyl acetate, acetone and methanol as the elutropic series of solvents. Concentration *in vacuo* of the combined fractions containing pure product gave the title compound as a colourless solid (0.061g, 57%).

MH+ 409.

Example 2

4-[4-(Methylsulfonyl)phenyl]-N-(pyridin-3-ylmethyl)-6-(trifluoromethyl)pyrimidin-2-amine

To a stirred solution of 2-(methylsulfonyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (0.10g, 0.26mmol) in MeCN (3ml) was added 3-(aminomethyl)-pyridine (169mg, 6eq) and the resultant solution heated under reflux for 3h. The cooled reaction mixture was concentrated *in vacuo* and the resulting oil purified by SPE chromatography with chloroform then chloroform:methanol (50:1) as eluant. This gave the title compound as a yellow solid (100mg, 93%).

MH+ 409.

Example 34-[4-(Methylsulfonyl)phenyl]-N-(pyridin-2-ylmethyl)-6-(trifluoromethyl)pyrimidin-2-amine


To a stirred solution of 2-(methylsulfonyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (0.10g, 0.26mmol) in MeCN (4ml) was added 2-(aminomethyl)-pyridine (0.14, 5eq) and the resultant solution heated under reflux for 3h. The cooled reaction mixture was concentrated *in vacuo* and purified by SPE chromatography using chloroform, diethyl ether, ethyl acetate, acetone and methanol as the elutropic series of solvents. Concentration *in vacuo* of the combined fractions containing pure product gave the title compound as a colourless solid (0.086g, 80%).
MH+ 409.

Example 44-[4-(Methylsulfonyl)phenyl]-N-(phenylmethyl)-6-(trifluoromethyl)-2-pyrimidinamine

To a stirred solution of 2-(Methylsulfonyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (0.10g, 0.26mmol) in MeCN (4ml) was added benzylamine (5eq) and the resultant solution heated under reflux for 24h. The cooled reaction mixture was concentrated *in vacuo* and purified by SPE chromatography with cyclohexane:ethyl acetate (3:1). Concentration *in vacuo* of the combined fractions containing pure product gave the title compound as a white solid (0.090g, 80%).
MH+ 407.


The Examples of Table 1 were prepared in the manner described for Examples 1 to 4.

Table 1



Ex	n	R ¹	R ²	R ³	R ⁴	A	MS
5	1	(1R)-CH ₃	H	CH ₃	H	phenyl	MH+ 422
6	1	(1S)-CH ₃	H	CH ₃	H	phenyl	MH+ 422
7	1	CH ₃	CH ₃	CH ₃	H	phenyl	MH+ 436
8	1	H	H	CH ₃	H	3-methoxyphenyl	no ion
9	1	H	H	CH ₃	H	4-methoxyphenyl	MH+ 438
10	1	H	H	CH ₃	H	4-trifluoromethoxyphenyl	MH+ 492
11	1	H	H	CH ₃	H	3,4-difluorophenyl	MH+ 444
12	1	H	H	CH ₃	H	4-trifluoromethylphenyl	MH+ 476
13	1	H	H	CH ₃	H	4-methylphenyl	MH+ 422
14	1	H	H	CH ₃	H	3-fluorophenyl	MH+ 426
15	1	H	H	CH ₃	H	4-fluorophenyl	MH+ 426
16	1	H	H	CH ₃	H	3,5-difluorophenyl	MH+ 444
17	1	H	H	CH ₃	H	2,5-difluorophenyl	MH+ 444
18	1	H	H	CH ₃	H	2,6-difluorophenyl	MH+ 444
19	1	H	H	CH ₃	H	2,4-difluorophenyl	MH+ 444
20	1	H	H	CH ₃	H	4-difluoromethoxyphenyl	MH+ 474
21	1	H	H	CH ₃	H	3-methylphenyl	MH+ 422

Table 1



Ex	n	R ¹	R ²	R ³	R ⁴	A	MS
22	1	H	H	CH ₃	H	2-fluorophenyl	MH+ 426
23	1	H	H	CH ₃	H	3-chlorophenyl	MH+ 442
24	2	H	H	CH ₃	H	2-pyridyl	MH+ 423
25	1	H	H	CH ₃	H	2-furyl	MH+ 398
26	1	H	H	CH ₃	CH ₃	phenyl	MH+ 422
27	3	H	H	CH ₃	H	phenyl	MH+ 426
28	1	H	H	CH ₃	H	5-methyl-2-thienyl	MH+ 428
29	1	H	H	CH ₃	H	4-methyl-2-thiazolyl	MH+ 429

Example 30N-(4-methoxybenzyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine

- 5 A stirred solution of 2-(methylsulfonyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (1g, 2.629mmol) in N-methylpyrrolidone (10ml) was treated with 4-methoxybenzylamine (0.69ml). The mixture was stirred at room temperature for 18h and was then diluted with water (50ml). This gave a cream solid, which was triturated with diethyl ether giving the title compound as a
- 10 colourless solid (0.98g).
MH+ = 438

Example 31


N-[(4-fluorobenzyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine

A stirred solution of 2-(methylsulfonyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (1g, 2.629mmol) in N-methylpyrrolidone (10ml) was treated with 4-fluorobenzylamine (0.60ml). The mixture was stirred at room temp for 18h and was then diluted with water (50ml). This gave the title compound as a colourless solid which was collected by filtration and dried (0.72g).

MH+ = 426.

The Examples of Table 2 were prepared in the manner described for Examples 30 and 31.

Table 2



Ex	n	R ¹	R ²	R ³	R ⁴	A	MS
32	1	H	H	CH ₃	H	1,5-dimethyl-2-pyrrolyl	MH+ 425
33	1	H	H	CH ₃	H	3-methyl-2-thienyl	MH+ 428
34	1	H	H	CH ₃	H	3-thienyl	MH+ 414
35	1	H	H	CH ₃	H	5-methyl-2-furanyl	MH+ 412
36	1	H	H	CH ₃	H	6-methyl-2-pyridyl	MH+ 423

15 Example 37


N-[(5-methyl-1H-imidazol-4-yl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine

A solution of crude (5-methyl-1H-imidazol-4-yl)methyl[4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-yl]formamide (0.27g,

- 0.615mmol) in ethanol (10ml) and 2N hydrochloric acid (10ml) was heated under reflux for 2h. The solvents were then evaporated and the residue basified with 0.880 ammonia and extracted with DCM. The dried organic phase was evaporated onto silica gel and this mixture was purified on a silica gel SPE cartridge. Elution with DCM:ethanol:0.880 ammonia, 91:8:1, gave the title compound as a colourless crystalline solid (0.14g).
 MH+= 412.

- The Examples of Table 3 were prepared in the manner described for Example 37.

Table 3



Ex	n	R ¹	R ²	R ³	R ⁴	A	MS
38	1	H	H	CH ₃	H	5-methyl-4-(1H)imidazolyl	MH+ 412
39	1	H	H	CH ₃	H	5-methyl-3-isoxazolyl	MH+ 413
40	1	H	H	CH ₃	H	2-fluoro-4-pyridyl	MH+ 455

Example 41 - Tablets

- | | | |
|----|-----------------------------------|---------|
| a) | Compound of the invention | 5.0mg |
| | Lactose | 95.0mg |
| 15 | Microcrystalline Cellulose | 90.0mg |
| | Cross-linked polyvinylpyrrolidone | 8.0mg |
| | Magnesium Stearate | 2.0mg |
| | Compression weight | 200.0mg |

- The compound of the invention, microcrystalline cellulose, lactose and cross-linked polyvinylpyrrolidone are sieved through a 500 micron sieve and blended in a suitable mixer. The magnesium stearate is sieved through a 250 micron sieve

and blended with the active blend. The blend is compressed into tablets using suitable punches.

5	b)	Compound of the invention	5.0mg
		Lactose	165.0mg
		Pregelatinised Starch	20.0mg
		Cross-linked polyvinylpyrrolidone	8.0mg
		Magnesium Stearate	<u>2.0mg</u>
		Compression weight	200.0mg

10 The compound of the invention, lactose and pregelatinised starch are blended together and granulated with water. The wet mass is dried and milled. The magnesium stearate and cross-linked polyvinylpyrrolidone are screened through a 250 micron sieve and blended with the granule. The resultant blend is compressed using suitable tablet punches.

Example 42 - Capsules

15	a)	Compound of the invention	5.0mg
		Lactose	193.0mg
		Magnesium Stearate	<u>2.0mg</u>
		Fill weight	200.0mg

20 The compound of the invention and pregelatinised starch are screened through a 500 micron mesh sieve, blended together and lubricated with magnesium stearate, (meshed through a 250 micron sieve). The blend is filled into hard gelatine capsules of a suitable size.

25	b)	Compound of the invention	5.0mg
		Lactose	177.0mg
		Polyvinylpyrrolidone	8.0mg
		Cross-linked polyvinylpyrrolidone	8.0mg
		Magnesium Stearate	<u>2.0mg</u>
		Fill weight	200.0mg

30 The compound of the invention and lactose are blended together and granulated with a solution of polyvinylpyrrolidone. The wet mass is dried and milled. The magnesium stearate and cross-linked polyvinylpyrrolidone are screened through

a 250 micron sieve and blended with the granules. The resultant blend is filled into hard gelatine capsules of a suitable size.

Example 43 - Syrup

5	a)	Compound of the invention	5.0mg
		Hydroxypropyl Methylcellulose	45.0mg
		Propyl Hydroxybenzoate	1.5mg
		Butyl Hydroxybenzoate	0.75mg
		Saccharin Sodium	5.0mg
10		Sorbitol Solution	1.0ml
		Suitable Buffers	qs
		Suitable flavours	qs
		Purified Water to	10.0ml

15 The hydroxypropyl methylcellulose is dispersed in a portion of hot purified water together with the hydroxybenzoates and the solution is allowed to cool to ambient temperature. The saccharin, sodium flavours and sorbitol solution are added to the bulk solution. The compound of the invention is dissolved in a portion of the remaining water and added to the bulk solution. Suitable buffers may be added to control the pH in the region of maximum stability. The solution
20 is made up to volume, filtered and filled into suitable containers.

Example 44 - Injection Formulation

		% w/v
	Compound of the invention	1.00
	Water for injections B.P. to	100.00
25	Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted to that of maximum stability and/or to facilitate solution of the compound of the invention using dilute acid or alkali or by the addition of suitable buffer salts. Solubilisers, such as cosolvents, may also be added to facilitate solution of the compound of the invention. Antioxidants and metal chelating salts may also be included. The solution is clarified, made up to final volume with water and the pH remeasured and adjusted if necessary, to provide 10mg/ml of the compound of formula (I).	
30		

The solution may be packaged for injection, for example by filling and sealing in ampoules, vials or syringes. The ampoules, vials or syringes may be aseptically filled (e.g. the solution may be sterilised by filtration and filled into sterile ampoules under aseptic conditions) and/or terminally sterilised (e.g. by heating in an autoclave using one of the acceptable cycles). The solution may be packed under an inert atmosphere of nitrogen.

Preferably the solution is filled into ampoules, sealed by fusion of the glass and terminally sterilised.

Further sterile formulations are prepared in a similar manner containing 0.5, 2.0 and 5% w/v of the compound of the invention, so as to provide respectively 5, 20 and 50mg/ml of the compound of the invention.

Biological Data

Inhibitory activity against human COX-1 and COX-2 was assessed in COS cells which had been stably transfected with cDNA for human COX-1 and human COX-2. 24 Hours prior to experiment, COS cells were transferred from the 175cm² flasks in which they were grown, onto 24-well cell culture plates using the following procedure. The incubation medium (Dulbecco's modified eagles medium (DMEM) supplemented with heat-inactivated foetal calf serum (10%v/v), penicillin (100 IU/ml), streptomycin (100µg/ml) and geneticin (600µg/ml)) was removed from a flask of confluent cells (1 flask at confluency contains approximately 1x10⁷ cells). 10ml of phosphate buffered saline (PBS) was added to the flask to wash the cells. Having discarded the PBS, cells were then rinsed in 10ml trypsin for 20 seconds, after which the trypsin was removed and the flask placed in an incubator (37°) for 1-2 minutes until cells became detached from the flask. The flask was then removed from the incubator and cells resuspended in 10ml of fresh incubation medium. The contents of the flask was transferred to a 250ml sterile container and the volume of incubation medium subsequently made up to 100ml. 1ml cell suspension was pipetted into each well of 4x24-well cell culture plates. The plates were then placed in an incubator (37°C, 95% air/5% CO₂) overnight. If more than 1 flask of cells were required, the cells from the individual flasks were combined before being dispensed into the 24-well plates.


Following the overnight incubation, the incubation medium was completely removed from the 24-well cell culture plates and replaced with 250 μ l fresh DMEM (37°C). The test compounds were made up to 250x the required test concentration in DMSO and were added to the wells in a volume of 1 μ l. Plates were then mixed gently by swirling and then placed in an incubator for 1 hour (37°C, 95% air/5% CO₂). Following the incubation period, 10 μ l of arachidonic acid (750 μ M) was added to each well to give a final arachidonic acid concentration of 30 μ M. Plates were then incubated for a further 15 minutes, after which the incubation medium was removed from each well of the plates and stored at -20°C, prior to determination of prostaglandin E₂ (PGE₂) levels using enzyme immunoassay. The inhibitory potency of the test compound was expressed as an IC₅₀ value, which is defined as the concentration of the compound required to inhibit the PGE₂ release from the cells by 50%. The selectivity ratio of inhibition of COX-1 versus COX-2 was calculated by comparing respective IC₅₀ values.

The following IC₅₀ values for inhibition of COX-2 and COX-1 were obtained for compounds of the invention:

Example No.	COX-2: IC ₅₀ (nM)	COX-1: IC ₅₀ (nM)
1	1.3	>100,000
2	10.8	>100,000
3	2.5	>100,000
4	0.25	>100,000
9, 30	34	>100,000
15, 31	0.28	>100,000

CLAIMS


1. Compounds of formula (I)



and pharmaceutically acceptable derivatives thereof, in which:


- 5 R^1 and R^2 are independently selected from H, or C_{1-6} alkyl;
 R^3 is C_{1-6} alkyl or NH_2 ;
 R^4 is H or C_{1-6} alkyl;
A is a 5- or 6-membered aryl, or a 5- or 6-membered aryl substituted by one or more R^5 ;
- 10 R^5 is halogen, C_{1-6} alkyl, C_{1-6} alkyl substituted by one or more F, C_{1-6} alkoxy, C_{1-6} alkoxy substituted by one or more F, SO_2NH_2 or SO_2C_{1-6} alkyl; and
n is 1 to 4.
2. Compounds as claimed in claim 1 wherein R^1 and R^2 are independently selected from H and methyl.
- 15 3. Compounds as claimed in claim 1 or 2 wherein R^3 is C_{1-6} alkyl, such as C_{1-3} alkyl (e.g. methyl).
4. Compounds as claimed in any of claims 1 to 3 wherein R^4 is H or C_{1-3} alkyl, such as methyl.

5. Compounds as claimed in any of claims 1 to 4 wherein A is selected from



and A is unsubstituted or substituted by one or two R^5 (e.g. one R^5).

- 5 6. Compounds as claimed in any of claims 1 to 5 wherein R^5 is halogen (e.g. F), C_{1-3} alkyl (e.g. methyl), C_{1-3} alkyl substituted by one to three F (e.g. CF_3), C_{1-3} alkoxy (e.g. methoxy), C_{1-3} alkoxy substituted by one to three F (e.g. $OCHF_2$ or OCF_3), or $SONH_2$.
- 10 7. Compounds as claimed in any of claims 1 to 6 wherein n is 1 to 3 (e.g. 1).
8. Compounds as claimed in any of claims 1 to 7 wherein R^1 and R^2 are independently selected from H or methyl; R^3 is C_{1-6} alkyl, such as C_{1-3} alkyl (e.g. methyl); R^4 is H or C_{1-3} alkyl, such as methyl; A is selected from



15

and is unsubstituted or substituted by one or two R^5 (e.g. one R^5); R^5 is halogen (e.g. F), C_{1-3} alkyl (e.g. methyl), C_{1-3} alkyl substituted by one to three F (e.g. CF_3),

C₁₋₃alkoxy (e.g. methoxy), C₁₋₃alkoxy substituted by one to three F (e.g. OCHF₂ or OCF₃), or SONH₂; and n is 1 to 3 (e.g. 1).

9. Compounds as claimed in any of claims 1 to 8 wherein A is selected from



5 10. Compounds as claimed in any of claims 1 to 9 wherein R⁵ is halogen (e.g. F) or C₁₋₆alkoxy, such as C₁₋₃alkoxy (e.g. methoxy).

11. Compounds as claimed in any of claims 1 to 10 wherein R¹ and R² are both H.

10

12.

4-[4-(methylsulfonyl)phenyl]-N-(pyridin-4-ylmethyl)-6-(trifluoromethyl)pyrimidin-2-amine;

4-[4-(methylsulfonyl)phenyl]-N-(pyridin-3-ylmethyl)-6-(trifluoromethyl)pyrimidin-2-amine;

15

4-[4-(methylsulfonyl)phenyl]-N-(pyridin-2-ylmethyl)-6-(trifluoromethyl)pyrimidin-2-amine;

4-[4-(methylsulfonyl)phenyl]-N-(phenylmethyl)-6-(trifluoromethyl)-2-pyrimidinamine;

20


N-(4-methoxybenzyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine;

N-(4-fluorobenzyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine;

and pharmaceutically acceptable derivatives thereof.


13. A process for the preparation of compounds of formula (I) and pharmaceutically acceptable derivatives thereof as defined in any one of claims 1 to 12, which comprises:

- 5 (A), reacting an amine $\text{HNR}^4(\text{CR}^1\text{R}^2)_n\text{-A}$ of formula (II) or a protected derivative thereof with a compound of formula (III)



or a protected derivative thereof; or

- (B), reacting an alkyl halide $\text{Hal-(CR}^1\text{R}^2)_n\text{-A}$ of formula (XII) or a protected derivative thereof with a compound of formula (XIII)



10

or a protected derivative thereof; or

- (C), interconversion of a compound of formula (I) into another compound of formula (I); or

- (D), deprotecting a protected derivative of a compound of formula (I); and

- 15 optionally converting compounds of formula (I) prepared by any one of processes (A) to (D) into pharmaceutically acceptable derivatives thereof.

14. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1

to 12 in admixture with one or more physiologically acceptable carriers or excipients.

5 15. A compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 12 for use in human or veterinary medicine.

10 16. A method of treating a human or animal subject suffering from a condition which is mediated by COX-2 which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative as defined in any one of claims 1 to 12.

15 17. A method of treating a human or animal subject suffering from an inflammatory disorder, which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 12.

18. The use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 12 for the manufacture of a therapeutic agent for the treatment of a condition which is mediated by COX-2.

20 19. The use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 12 for the manufacture of a therapeutic agent for the treatment of an inflammatory disorder.

20. A compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 12 for use in the treatment of a condition which is mediated by COX-2.

INTERNATIONAL SEARCH REPORT

Inter'l Application No.

PCT/GB 01/00511

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/42 C07D401/12 C07D407/12 C07D409/12 C07D417/12
 A61K31/505 A61K31/506 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category * Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

A WO 98 24782 A (AMGEN INC ;MANTLO NATHAN B
 (US); SPOHR ULRIKE D (US); MALONE MICHA)
 11 June 1998 (1998-06-11)
 claims 1,29

1-20

A WO 98 03484 A (GAUTHIER JACQUES YVES
 ;MERCK FROSST CANADA INC (CA); DUBE DANIEL
 () 29 January 1998 (1998-01-29)
 claims 12,15,18,19

1-20

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

7 May 2001

Date of mailing of the international search report

16 May 2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Seymour, L

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 16 and 17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

Intel. Application No
PCT/GB 01/00511

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9824782 A	11-06-1998	AU 5525498 A	29-06-1998
		AU 6012098 A	29-06-1998
		BG 103512 A	31-07-2000
		BG 103521 A	31-07-2000
		BR 9713850 A	29-02-2000
		BR 9713863 A	14-03-2000
		CN 1246857 A	08-03-2000
		CN 1246858 A	08-03-2000
		CZ 9902015 A	17-11-1999
		CZ 9902016 A	17-11-1999
		EP 0948496 A	13-10-1999
		EP 0948497 A	13-10-1999
		WO 9824780 A	11-06-1998
WO 9803484 A	29-01-1998	AU 723179 B	17-08-2000
		AU 3331997 A	10-02-1998
		BG 103179 A	30-11-1999
		CA 2260016 A	29-01-1998
		CZ 9900130 A	16-06-1999
		EP 0912518 A	06-05-1999
		HR 970389 A	30-06-1998
		JP 11514008 T	30-11-1999
		NO 990191 A	16-03-1999
		PL 330995 A	21-06-1999
		SK 3699 A	10-12-1999
		TR 9900046 T	21-04-1999
		BR 9710372 A	17-08-1999
		HU 9903974 A	28-03-2000
		US 6001843 A	14-12-1999
		US 6071936 A	06-06-2000
		US 5861419 A	19-01-1999